3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
7
Phase 1/2
2
Phase 3
1
Phase 1
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Breast Neoplasms
14
Carcinoma, Non-Small-Cell Lung
11
Lung Neoplasms
9
Pancreatic Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
7
Head and Neck Neoplasms
7
Colorectal Neoplasms
7
Ovarian Neoplasms
6
Neoplasm Metastasis
6
Carcinoma, Hepatocellular
6
Triple Negative Breast Neoplasms
5
Urinary Bladder Neoplasms
4
Neoplasms
4
Lymphoma, Large B-Cell, Diffuse
4
Biliary Tract Neoplasms
4
Stomach Neoplasms
3
Small Cell Lung Carcinoma
3
Prostatic Neoplasms
3
Lymphoma, Follicular
3
Kidney Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Squamous Cell
3
Carcinoma, Renal Cell
3
Carcinoma
3
Adenocarcinoma Of Esophagus
3
Uterine Cervical Neoplasms
2
Recurrence
2
Oropharyngeal Neoplasms
2
Non-Muscle Invasive Bladder Neoplasms
2
Lymphoma, T-Cell, Cutaneous
2
Interventions
pembrolizumab
26
Nivolumab
10
Cisplatin
9
Gemcitabine
8
Docetaxel
6
enfortumab vedotin
5
atezolizumab
5
Ipilimumab
5
Carboplatin
5
sacituzumab govitecan
4
Paclitaxel
4
Pemetrexed
3
Cyclophosphamide
3
vofatamab
2
tremelimumab
2
tislelizumab
2
regorafenib
2
lenvatinib
2
epacadostat
2
durvalumab
2
avelumab
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Biopsy
2
Bevacizumab
2
B701 protein, Human herpesvirus 6
2
ALT-803
2
yeast-CEA vaccine
1
toripalimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma, Transitional Cell
×
durvalumab
×
Clear all
NCT03317158
2026-04-15
ADAPT-BLADDER
Hoosier Cancer Research Network
Phase 1/2
Recruiting
55 enrolled
NCT03871036
2025-03-06
ICRA
The Netherlands Cancer Institute
Phase 1/2
Completed
53 enrolled